GLP-1 class comparison: Tirzepatide, Retatrutide, Mazdutide, Survodutide
Four next-generation GLP-1-family peptides compared on receptor profile, clinical status, supply economics, and how to pick the right molecule for your research or compounding pipeline.
Published May 12, 2026 · 11 min read · By PeptideXpo Regulatory Team
The GLP-1 class has become the most active area of metabolic peptide research and the most procurement-relevant for compounding pharmacy buyers. Beyond Semaglutide (the GLP-1 mono-agonist anchor of the class), four next-generation molecules now dominate buyer inquiries: Tirzepatide, Retatrutide, Mazdutide, and Survodutide. They differ on receptor coverage, clinical-development stage, and supply economics, and choosing between them depends on what your workflow actually needs.
Receptor profiles
| Molecule | GLP-1R | GIPR | GCGR |
|---|---|---|---|
| Semaglutide | ✅ | , | , |
| Tirzepatide | ✅ | ✅ | , |
| Mazdutide | ✅ | , | ✅ |
| Survodutide | ✅ | , | ✅ |
| Retatrutide | ✅ | ✅ | ✅ |
The presence or absence of each receptor arm has predictable biological consequences:
- GLP-1R: the foundational arm; drives glycemic control, satiety, and most of the weight-reduction signal.
- GIPR: incretin reinforcement; in combination with GLP-1R agonism produces larger glycemic and weight effects than GLP-1R alone.
- GCGR: hepatic energy expenditure; adds direct metabolic-rate effects beyond the incretin axis.
Clinical-development status
| Molecule | Stage | Sponsor |
|---|---|---|
| Tirzepatide | Approved (Mounjaro, Zepbound) | Eli Lilly |
| Mazdutide | Phase 3 (China-focused) | Innovent / Eli Lilly |
| Survodutide | Phase 3 | Boehringer Ingelheim / Zealand Pharma |
| Retatrutide | Phase 3 | Eli Lilly |
Tirzepatide is the only one with finished-drug approval. Retatrutide has the most aggressive published efficacy signals in Phase 2 (-24% body weight at 48 weeks in the highest-dose arm) but is still in development.
Supply economics
Bulk pricing per mg follows aggregate production volume:
- Tirzepatide and Semaglutide have the largest production volumes and the lowest per-mg pricing.
- Liraglutide is older with established production capacity, similar economics.
- Retatrutide, Mazdutide, Survodutide have lower aggregate volumes, per-mg pricing is materially higher and lead times longer (14-21 days vs 7-14 days for Tirzepatide).
Pricing improves substantially at the 100 g and 1 kg break points, and again on recurring-order pricing against a locked synthesis route.
How to choose
For research workflows studying GLP-1-pathway pharmacology specifically: Semaglutide is the cleanest tool (GLP-1 mono-agonist, broad clinical reference data).
For research workflows studying incretin-mechanism additivity: Tirzepatide (GIP+GLP-1) isolates the incretin-pair mechanism without glucagon-pathway confounding.
For research workflows studying glucagon-pathway contributions in isolation from GIP: Mazdutide or Survodutide (both GLP-1+glucagon, no GIP).
For research workflows studying maximum tri-mechanism effects: Retatrutide (GIP+GLP-1+glucagon).
For compounding pharmacy workflows: Tirzepatide and Semaglutide are the cleanest procurement targets because of the approved-drug pedigree and the broader vial-size flexibility. Compounding eligibility depends on the destination market's current shortage / regulatory posture for each; verify at the time of dispense.
Analytical considerations across the class
All five molecules are ≥30-amino-acid lipidated peptides synthesized by SPPS, and all share similar analytical packets: HPLC, mass spec, water content, counter-ion. Two practical points:
- **Acetate is the default salt form across the class**, preferred over TFA because residual TFA can suppress observed potency in cell-based assays.
- **Sequence verification by LC-MS/MS is recommended at first-time supplier qualification** for all five, the sequences are long enough (31-39 amino acids) that mass-alone identity confirmation leaves room for deletion-sequence ambiguity.
What's coming next
The GLP-1-class development pipeline is dense. Beyond the four molecules above, dual-agonists targeting GLP-1 plus other targets (amylin, FGF21, leptin, glucagon variants) are in earlier clinical and pre-clinical development. The CagriSema combination (Cagrilintide + Semaglutide) is a near-term entry that adds amylin-axis activity to GLP-1 mono-agonism. For procurement teams, the operational implication is that the GLP-1 catalog will continue expanding for at least the next 24-36 months; building durable supplier relationships now is more valuable than optimizing pricing on any single molecule.